Early Biomarkers for Insulin Resistance
Early detection of pre-diabetes has important implications for patient care and drug discovery. Metabolon’s technology is uniquely positioned to identify biomarkers, accelerate MOA, further personalized medicine and tailor therapy approaches.
A recent study in The Lancet determined that 347 million adults are affected by diabetes. Current methodology for measuring insulin resistance (IR) is limited and lacks early detection capabilities.